A phase III clinical study exploring the use of Xarelto (rivaroxaban) in preventing strokes and embolism in recent stroke patients has been stopped because Xarelto showed no more efficacy than the current recommended care, low doses of aspirin, while also demonstrating higher bleeding rates than aspirin. Study “Stopping Early for... Read more »